The new products will be aimed at the growing number of federal jurisdictions worldwide that have or will legalise cannabinoids, such as Canada, for medicinal and/or adult use.
As Neptune is rapidly executing on its strategy and business plan, the corporation will fund research and development activities to clinically support the benefits of cannabinoids in combination with krill oil.
As indicated by prior research, the corporation believes the unique properties of krill oil lend the ability to enhance absorption of orally-administered lipid-soluble compounds, which could be especially beneficial for molecules such as CBD.
Neptune's research activities will also include other oils, ingredients and technologies such as MaxSimil, a patented omega-3 fatty acid delivery technology that may enhance the absorption of lipid-based nutraceuticals and a variety of other marine and seed oils.
"We are proud to have reached an exclusive research agreement with one of the largest krill oil providers in the world. We are confident that our R&D efforts with cannabinoids can lead to the development of new formulations for medical and wellness products addressing health issues such as pain, sleep, anxiety and stress."
"As the regulatory frameworks for medical cannabis use and legalisation of cannabinoids in Canada and other jurisdictions around the world progress, our key competitive and distinctive advantages remain our scientific, regulatory, extraction, formulation and global commercialisation capabilities," said Jim Hamilton, President and CEO of Neptune.
